Direct Extracellular NAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling. Transcriptional Regulation by SOX and HIF-2α

Autor: Belinda L. Sun, Sara M. Camp, Heather Lynn, Ankit A. Desai, Xiaoguang Sun, Haiyang Tang, Rebecca Vanderpool, Franz Rischard, Jason X.-J. Yuan, Aleksandra Babicheva, Nancy Casanova, Liliana Moreno-Vinasco, Jian Wang, Geetanjali Gupta, Carrie L. Kempf, Mohamed Ahmed, Joe G.N. Garcia, Saad Sammani, Radu C. Oita, Akash Gupta
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Pulmonary and Respiratory Medicine
Transcription
Genetic

Hypertension
Pulmonary

medicine.medical_treatment
Clinical Biochemistry
Nicotinamide phosphoribosyltransferase
Vascular Remodeling
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Basic Helix-Loop-Helix Transcription Factors
medicine
Transcriptional regulation
Animals
Humans
Nicotinamide Phosphoribosyltransferase
Molecular Biology
Transcription factor
Cells
Cultured

SOX Transcription Factors
STAT5
Original Research
biology
Growth factor
Endothelial Cells
Cell Biology
Rats
Vascular endothelial growth factor
Disease Models
Animal

030104 developmental biology
Gene Expression Regulation
030228 respiratory system
chemistry
Cancer research
biology.protein
STAT protein
Cytokines
Female
Platelet-derived growth factor receptor
Zdroj: Am J Respir Cell Mol Biol
ISSN: 1535-4989
1044-1549
Popis: We previously demonstrated involvement of NAMPT (nicotinamide phosphoribosyltransferase) in pulmonary arterial hypertension (PAH) and now examine NAMPT regulation and extracellular NAMPT’s (eNAMPT’s) role in PAH vascular remodeling. NAMPT transcription and protein expression in human lung endothelial cells were assessed in response to PAH-relevant stimuli (PDGF [platelet-derived growth factor], VEGF [vascular endothelial growth factor], TGF-β1 [transforming growth factor-β1], and hypoxia). Endothelial-to-mesenchymal transition was detected by SNAI1 (snail family transcriptional repressor 1) and PECAM1 (platelet endothelial cell adhesion molecule 1) immunofluorescence. An eNAMPT-neutralizing polyclonal antibody was tested in a PAH model of monocrotaline challenge in rats. Plasma eNAMPT concentrations, significantly increased in patients with idiopathic pulmonary arterial hypertension, were highly correlated with indices of PAH severity. eNAMPT increased endothelial-to-mesenchymal transition, and each PAH stimulus significantly increased endothelial cell NAMPT promoter activity involving transcription factors STAT5 (signal transducer and activator of transcription 5), SOX18 (SRY-box transcription factor 18), and SOX17 (SRY-box transcription factor 17), a PAH candidate gene newly defined by genome-wide association study. The hypoxia-induced transcription factor HIF-2α (hypoxia-inducible factor-2α) also potently regulated NAMPT promoter activity, and HIF-2α binding sites were identified between −628 bp and −328 bp. The PHD2 (prolyl hydroxylase domain-containing protein 2) inhibitor FG-4592 significantly increased NAMPT promoter activity and protein expression in an HIF-2α–dependent manner. Finally, the eNAMPT-neutralizing polyclonal antibody significantly reduced monocrotaline-induced vascular remodeling, PAH hemodynamic alterations, and NF-κB activation. eNAMPT is a novel and attractive therapeutic target essential to PAH vascular remodeling.
Databáze: OpenAIRE